The discount rate is supposed to reflect the risk free rate of return (i.e. what could you get as a return 'risk free' as an alternative). US Treasuries are often used or a companies WACC. And whilst many pundits increase the discount rate to reflect any increased risk (say looking at a small cap volatile cashflows vs a large cap or a large cap miner with mines in Africa vs mines in Australia, or looking at a clinical stage biotech vs a BP) KJT already provided for this risk by discounting the value (chance) of each cashflow separately rather than putting it in the discount rate.
So while he may have used a 8-12% as the 'discount rate' some of those cashflows were only given a % chance of occurring based on average approvals which effectively increases the discount rate (a 50% chance of getting approval applied equates to a doubling of the discount rate used, a 33% chance triples the discount rate applied, etc)
Not sure what discount rate was used by @Kjt1969 though?
- Forums
- ASX - By Stock
- Pipeline-in-a-drug
NEU
neuren pharmaceuticals limited
Add to My Watchlist
6.69%
!
$14.20

The discount rate is supposed to reflect the risk free rate of...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B |
Open | High | Low | Value | Volume |
$13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | $14.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.23 | 3278 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1300 | 14.030 |
1 | 500 | 14.000 |
1 | 357 | 13.970 |
1 | 30 | 13.900 |
1 | 700 | 13.700 |
Price($) | Vol. | No. |
---|---|---|
14.260 | 2920 | 1 |
14.300 | 1000 | 1 |
14.380 | 72 | 1 |
14.400 | 1000 | 1 |
14.460 | 434 | 1 |
Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online